Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Terminado
ClinicalTrials.gov
A Prospective Natural History Study of Progression of Physical Impairment, Activity Limitation and Quality of Life in Duchenne Muscular Dystrophy.
OBSERVATIONAL
Inicio: 1 de sept de 2012
ID: NCT01753804
Completado
Fase 3
ClinicalTrials.gov
An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens
INTERVENTIONAL
Inicio: 1 de ene de 2013
ID: NCT01644643
Completado
Fase 3
ClinicalTrials.gov
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
INTERVENTIONAL
Inicio: 9 de jul de 2015
ID: NCT02446899
Terminado
Fase 3
ClinicalTrials.gov
An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents
INTERVENTIONAL
Inicio: 25 de may de 2018
ID: NCT03567291
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Double-blind, Placebo Controlled Multi-center Study of Subcutaneous Secukinumab (150 mg and 300 mg) in Prefilled Syringe to Demonstrate Efficacy (Including Inhibition of Structural Damage), Safety, and Tolerability up to 2 Years in Subjects With Active Psoriatic Arthritis (FUTURE 5)
INTERVENTIONAL
Inicio: 31 de ago de 2015
ID: NCT02404350
Completado
Fase 3
ClinicalTrials.gov
A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Ramipril on Morbidity and Mortality in High Risk Patients Following an Acute Myocardial Infarction (AMI)
INTERVENTIONAL
Inicio: 9 de dic de 2016
ID: NCT02924727
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients
INTERVENTIONAL
Inicio: 2 de oct de 2013
ID: NCT01870778
Completado
Fase 3
ClinicalTrials.gov
A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/Day, Split-dose) in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
INTERVENTIONAL
Inicio: 1 de may de 2014
ID: NCT02160145
Activo, no recluta
Fase 2
ClinicalTrials.gov
A PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMBINATION WITH PF-07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
INTERVENTIONAL
Inicio: 14 de mar de 2022
ID: NCT05262400
Activo, no recluta
Fase 3
ClinicalTrials.gov
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA
INTERVENTIONAL
Inicio: 15 de ene de 2021
ID: NCT04657991
Completado
Fase 3
ClinicalTrials.gov
A PHASE 3 MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826-83) 20 MG OR 80 MG [OR TAFAMIDIS (PF-06291826-00) 61 MG] IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (ATTR-CM)
INTERVENTIONAL
Inicio: 13 de jun de 2016
ID: NCT02791230
Reclutando
Fase 2
ClinicalTrials.gov
A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 24 de ene de 2023
ID: NCT05563220
Reclutando
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
INTERVENTIONAL
Inicio: 9 de may de 2023
ID: NCT05716100
Completado
Fase 4
ClinicalTrials.gov
A Phase 4, Non-treatment Follow-up For Cardiac Assessments Following Use Of Smoking Cessation Treatments In Subjects With And Without A History Of Psychiatric Disorders
INTERVENTIONAL
Inicio: 1 de may de 2012
ID: NCT01574703
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma
INTERVENTIONAL
Inicio: 5 de abr de 2017
ID: NCT02972840
Completado
Fase 1
ClinicalTrials.gov
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Respiratory Combination Vaccine Candidates in Older Adults
INTERVENTIONAL
Inicio: 9 de mar de 2023
ID: NCT05788237
Completado
Fase 2
ClinicalTrials.gov
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Dose-finding Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)
INTERVENTIONAL
Inicio: 1 de ago de 2018
ID: NCT03437278
Terminado
Fase 3
ClinicalTrials.gov
A 2-treatment Period, Randomized, Placebo-controlled, Multicenter Parallel-group Study to Assess the Safety of QAW039 When Added to Existing Asthma Therapy in GINA Steps 3, 4 and 5 Patients With Uncontrolled Asthma.
INTERVENTIONAL
Inicio: 21 de mar de 2017
ID: NCT03052517
Completado
Fase 2
ClinicalTrials.gov
A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
INTERVENTIONAL
Inicio: 18 de abr de 2019
ID: NCT03845517
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome With Moderate-to-Severe Symptom State (HZNP-DAZ-303)
INTERVENTIONAL
Inicio: 8 de abr de 2024
ID: NCT06245408
Anterior
1
...
6
7
8
...
434
Siguiente
Filtros